世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

アフリベルセプト・バイオシミラーの世界市場レポート、歴史と予測 2018-2029


Global Aflibercept Biosimilars Market Report, History and Forecast 2018-2029

アフリベルセプトバイオシミラーの世界市場は、2022年に9億869.64万米ドルと推定され、2023年から2029年の予測期間中に1.41%のCAGRで成長し、2029年までに1億3994万米ドルの修正規模に達すると予測されている。 ... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2023年12月4日 US$3,350
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

アフリベルセプトバイオシミラーの世界市場は、2022年に9億869.64万米ドルと推定され、2023年から2029年の予測期間中に1.41%のCAGRで成長し、2029年までに1億3994万米ドルの修正規模に達すると予測されている。
アフリベルセプト・バイオシミラーの北米市場は、2022年に7億6,397万ドルと評価され、2023年から2029年の予測期間中に1.74%のCAGRで、2029年までに8億4,593万ドルに達すると予測される。
アフリベルセプト・バイオシミラーのアジア太平洋市場は、2022年に4億3,624万ドルと評価され、2023年から2029年の予測期間中に-2.22%のCAGRで、2029年までに3億8,496万ドルに達するだろう。
アフリベルセプトバイオシミラーの欧州市場は、2022年に1億7,354万ドルと評価され、2023年から2029年の予測期間中に0.78%のCAGRで、2029年までに1億5,376万ドルに達するだろう。

レポートの範囲
本レポートは、Afliberceptバイオシミラーの世界市場を定量的・定性的分析の両面から包括的に提示することを目的としており、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、Afliberceptバイオシミラーに関する十分な情報に基づいたビジネス上の意思決定を行えるよう支援します。

アフリベルセプトバイオシミラーの市場規模、推計、予測は、2022年を基準年とし、2018年から2029年までの期間の履歴と予測データを考慮した販売量(K単位)と収益(百万ドル)で提供します。当レポートでは、世界のアフリベルセプトバイオシミラー市場を包括的にセグメント化しています。製品タイプ別、用途別、プレイヤー別の地域別市場規模も掲載しています。
市場のより詳細な理解のために、競合状況、主要競合企業のプロフィール、それぞれの市場ランクを掲載しています。また、技術動向や新製品開発についても論じています。

本レポートは、読者が潜在的な利益を高めるために、業界内の競争と競争環境に対する戦略を理解するのに役立ちます。また、本レポートは世界のアフリベルセプトバイオシミラー市場の競争環境に焦点を当て、主要企業の市場シェア、業界ランキング、競合エコシステム、市場実績、新製品開発、経営状況、事業拡大、買収などを詳細に紹介しており、読者が主要競合企業を特定し、市場の競争パターンを深く理解するのに役立ちます。

市場セグメンテーション
当レポートでは、アフリベルセプトバイオシミラーのメーカー別、タイプ別、用途別、地域別、国別のセグメントを網羅し、2022年を基準年とした過去および予測期間(2018-2022年、2023-2029年)の市場規模(金額、数量、平均価格)およびCAGRを掲載しています。また、さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場に対する魅力的な投資提案マトリクスを解説しています。

企業別
リジェネロン社
バイエルヘルスケア
カンホンファーマ
バイオコン

タイプ別セグメント
2mg
8mg

用途別セグメント
病院
診療所
その他

地域別
北米
アメリカ
カナダ

アジア太平洋
中国
日本
韓国
インド
オーストラリア
東南アジア

ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア

ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
コロンビア

中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦

コアチャプター
第一章:本レポートの調査範囲、タイプ別市場セグメントのエグゼクティブサマリー、北米、欧州、アジア太平洋、中南米、中東&アフリカの市場規模セグメントを紹介します。
第二章:アフリベルセプトバイオシミラーメーカーの競争環境、価格、売上高、市場シェア、ランキング、最新の開発計画、M&A情報などを詳細に分析。
第三章地域別アフリベルセプトバイオシミラーの売上高、収益。各地域の市場規模と発展の可能性を定量的に分析し、今後の発展展望、世界の市場空間を紹介します。
第4章:用途別市場セグメント、北米、欧州、アジア太平洋、中南米、中東&アフリカの市場規模セグメントを紹介します。
第五章、第六章、第七章、第八章、第九章北アメリカ、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東&アフリカ、国別の売上高と収益。
第10章主要企業のプロファイルを提供し、製品の売上高、収益、価格、売上総利益率、製品紹介、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介します。
第11章産業チェーン、主要原材料、製造コスト、市場ダイナミクスを分析。市場力学、市場の最新動向、市場の推進要因と制限要因、業界メーカーが直面する課題とリスク、業界の関連政策の分析を紹介する。
第12章販売チャネル、流通業者、顧客の分析
第十三章調査結果と結論。

ページTOPに戻る


目次

1 Aflibercept Biosimilars Market Overview 1
1.1 Aflibercept Biosimilars Product Overview 1
1.2 Aflibercept Biosimilars Market by Type 3
1.2.1 2mg 3
1.2.2 8mg 4
1.3 Global Aflibercept Biosimilars Market Size by Type 6
1.3.1 Global Aflibercept Biosimilars Market Size Overview by Type (2018-2029) 7
1.3.2 Global Aflibercept Biosimilars Historic Market Size Review by Type (2018-2023) 8
1.3.3 Global Aflibercept Biosimilars Forecasted Market Size by Type (2024-2029) 10
1.4 Key Regions Market Size by Type 11
1.4.1 North America Aflibercept Biosimilars Sales Breakdown by Type (2018-2023) 11
1.4.2 Europe Aflibercept Biosimilars Sales Breakdown by Type (2018-2023) 13
1.4.3 Asia-Pacific Aflibercept Biosimilars Sales Breakdown by Type (2018-2023) 15
1.4.4 Latin America Aflibercept Biosimilars Sales Breakdown by Type (2018-2023) 17
1.4.5 Middle East and Africa Aflibercept Biosimilars Sales Breakdown by Type (2018-2023) 19
2 Aflibercept Biosimilars Market Competition by Company 22
2.1 Global Top Players by Aflibercept Biosimilars Sales (2018-2023) 22
2.2 Global Top Players by Aflibercept Biosimilars Revenue (2018-2023) 23
2.3 Global Top Players by Aflibercept Biosimilars Price (2018-2023) 24
2.4 Global Top Manufacturers Aflibercept Biosimilars Manufacturing Base Distribution, Sales Area, Product Type 25
2.5 Aflibercept Biosimilars Market Competitive Situation and Trends 25
2.5.1 Aflibercept Biosimilars Market Concentration Rate (2018-2023) 25
2.5.2 Global Largest Manufacturers by Aflibercept Biosimilars Sales and Revenue in 2022 26
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Aflibercept Biosimilars as of 2022) 27
2.7 Date of Key Manufacturers Enter into Aflibercept Biosimilars Market 28
2.8 Key Manufacturers Aflibercept Biosimilars Product Offered 28
2.9 Mergers & Acquisitions, Expansion 29
3 Aflibercept Biosimilars Status and Outlook by Region 32
3.1 Global Aflibercept Biosimilars Market Size and CAGR by Region: 2018 VS 2022 VS 2029 32
3.2 Global Aflibercept Biosimilars Historic Market Size by Region 32
3.2.1 Global Aflibercept Biosimilars Sales in Volume by Region (2018-2023) 32
3.2.2 Global Aflibercept Biosimilars Sales in Value by Region (2018-2023) 33
3.2.3 Global Aflibercept Biosimilars Sales (Volume & Value), Price and Gross Margin (2018-2023) 34
3.3 Global Aflibercept Biosimilars Forecasted Market Size by Region 34
3.3.1 Global Aflibercept Biosimilars Sales in Volume by Region (2024-2029) 34
3.3.2 Global Aflibercept Biosimilars Sales in Value by Region (2024-2029) 35
3.3.3 Global Aflibercept Biosimilars Sales (Volume & Value), Price and Gross Margin (2024-2029) 35
4 Aflibercept Biosimilars by Application 37
4.1 Aflibercept Biosimilars Market by Application 37
4.1.1 Hospitals 37
4.1.2 Clinics 38
4.1.3 Others 39
4.2 Global Aflibercept Biosimilars Market Size by Application 40
4.2.1 Global Aflibercept Biosimilars Market Size Overview by Application (2018-2029) 41
4.2.2 Global Aflibercept Biosimilars Historic Market Size Review by Application (2018-2023) 42
4.2.3 Global Aflibercept Biosimilars Forecasted Market Size by Application (2024-2029) 44
4.3 Key Regions Market Size by Application 46
4.3.1 North America Aflibercept Biosimilars Sales Breakdown by Application (2018-2023) 46
4.3.2 Europe Aflibercept Biosimilars Sales Breakdown by Application (2018-2023) 47
4.3.3 Asia-Pacific Aflibercept Biosimilars Sales Breakdown by Application (2018-2023) 49
4.3.4 Latin America Aflibercept Biosimilars Sales Breakdown by Application (2018-2023) 51
4.3.5 Middle East and Africa Aflibercept Biosimilars Sales Breakdown by Application (2018-2023) 53
5 North America Aflibercept Biosimilars by Country 56
5.1 North America Aflibercept Biosimilars Historic Market Size by Country 56
5.1.1 North America Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029 56
5.1.2 North America Aflibercept Biosimilars Sales in Volume by Country (2018-2023) 56
5.1.3 North America Aflibercept Biosimilars Sales in Value by Country (2018-2023) 57
5.2 North America Aflibercept Biosimilars Forecasted Market Size by Country 57
5.2.1 North America Aflibercept Biosimilars Sales in Volume by Country (2024-2029) 57
5.2.2 North America Aflibercept Biosimilars Sales in Value by Country (2024-2029) 58
6 Europe Aflibercept Biosimilars by Country 59
6.1 Europe Aflibercept Biosimilars Historic Market Size by Country 59
6.1.1 Europe Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029 59
6.1.2 Europe Aflibercept Biosimilars Sales in Volume by Country (2018-2023) 59
6.1.3 Europe Aflibercept Biosimilars Sales in Value by Country (2018-2023) 60
6.2 Europe Aflibercept Biosimilars Forecasted Market Size by Country 61
6.2.1 Europe Aflibercept Biosimilars Sales in Volume by Country (2024-2029) 61
6.2.2 Europe Aflibercept Biosimilars Sales in Value by Country (2024-2029) 62
7 Asia-Pacific Aflibercept Biosimilars by Region 63
7.1 Asia-Pacific Aflibercept Biosimilars Historic Market Size by Region 63
7.1.1 Asia-Pacific Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029 63
7.1.2 Asia-Pacific Aflibercept Biosimilars Sales in Volume by Region (2018-2023) 63
7.1.3 Asia-Pacific Aflibercept Biosimilars Sales in Value by Region (2018-2023) 64
7.2 Asia-Pacific Aflibercept Biosimilars Forecasted Market Size by Region 65
7.2.1 Asia-Pacific Aflibercept Biosimilars Sales in Volume by Region (2024-2029) 65
7.2.2 Asia-Pacific Aflibercept Biosimilars Sales in Value by Region (2024-2029) 66
8 Latin America Aflibercept Biosimilars by Country 67
8.1 Latin America Aflibercept Biosimilars Historic Market Size by Country 67
8.1.1 Latin America Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029 67
8.1.2 Latin America Aflibercept Biosimilars Sales in Volume by Country (2018-2023) 67
8.1.3 Latin America Aflibercept Biosimilars Sales in Value by Country (2018-2023) 68
8.2 Latin America Aflibercept Biosimilars Forecasted Market Size by Country 69
8.2.1 Latin America Aflibercept Biosimilars Sales in Volume by Country (2024-2029) 69
8.2.2 Latin America Aflibercept Biosimilars Sales in Value by Country (2024-2029) 69
9 Middle East and Africa Aflibercept Biosimilars by Country 71
9.1 Middle East and Africa Aflibercept Biosimilars Historic Market Size by Country 71
9.1.1 Middle East and Africa Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029 71
9.1.2 Middle East and Africa Aflibercept Biosimilars Sales in Volume by Country (2018-2023) 71
9.1.3 Middle East and Africa Aflibercept Biosimilars Sales in Value by Country (2018-2023) 72
9.2 Middle East and Africa Aflibercept Biosimilars Forecasted Market Size by Country 73
9.2.1 Middle East and Africa Aflibercept Biosimilars Sales in Volume by Country (2024-2029) 73
9.2.2 Middle East and Africa Aflibercept Biosimilars Sales in Value by Country (2024-2029) 73
10 Company Profiles 75
10.1 Regeneron Pharmaceuticals 75
10.1.1 Regeneron Pharmaceuticals Company Information 75
10.1.2 Regeneron Pharmaceuticals Introduction and Business Overview 76
10.1.3 Regeneron Pharmaceuticals Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023) 76
10.1.4 Regeneron Pharmaceuticals Aflibercept Biosimilars Products Offered 77
10.1.5 Regeneron Pharmaceuticals Recent Development 77
10.2 Bayer HealthCare 78
10.2.1 Bayer HealthCare Company Information 78
10.2.2 Bayer HealthCare Introduction and Business Overview 79
10.2.3 Bayer HealthCare Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023) 79
10.2.4 Bayer HealthCare Aflibercept Biosimilars Products Offered 79
10.2.5 Bayer HealthCare Recent Development 80
10.3 Kanghong Pharma 81
10.3.1 Kanghong Pharma Company Information 81
10.3.2 Kanghong Pharma Introduction and Business Overview 82
10.3.3 Kanghong Pharma Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023) 82
10.3.4 Kanghong Pharma Aflibercept Biosimilars Products Offered 83
10.3.5 Kanghong Pharma Recent Development 83
10.4 Biocon 84
10.4.1 Biocon Company Information 84
10.4.2 Biocon Introduction and Business Overview 85
10.4.3 Biocon Aflibercept Biosimilars Products Offered 86
10.4.4 Biocon Recent Development 86
10.5 AbbVie 86
10.5.1 AbbVie Company Information 87
10.5.2 AbbVie Introduction and Business Overview 87
10.5.3 AbbVie Aflibercept Biosimilars Products Offered 88
10.5.4 AbbVie Recent Development 88
10.6 Roche 88
10.6.1 Roche Company Information 89
10.6.2 Roche Introduction and Business Overview 89
10.6.3 Roche Aflibercept Biosimilars Products Offered 90
10.6.4 Roche Recent Development 90
10.7 Novartis 90
10.7.1 Novartis Company Information 91
10.7.2 Novartis Introduction and Business Overview 91
10.7.3 Novartis Aflibercept Biosimilars Products Offered 92
10.7.4 Novartis Recent Development 92
10.8 QILU Pharmaceutical 93
10.8.1 QILU Pharmaceutical Company Information 93
10.8.2 QILU Pharmaceutical Introduction and Business Overview 93
10.8.3 QILU Pharmaceutical Aflibercept Biosimilars Products Offered 94
10.8.4 QILU Pharmaceutical Recent Development 94
10.9 Regenxbio 95
10.9.1 Regenxbio Company Information 95
10.9.2 Regenxbio Introduction and Business Overview 96
10.9.3 Regenxbio Aflibercept Biosimilars Products Offered 96
10.9.4 Regenxbio Recent Development 96
10.10 Samsung Bioepis 97
10.10.1 Samsung Bioepis Company Information 97
10.10.2 Samsung Bioepis Introduction and Business Overview 97
10.10.3 Samsung Bioepis Aflibercept Biosimilars Products Offered 98
10.10.4 Samsung Bioepis Recent Development 98
10.11 Amgen 99
10.11.1 Amgen Company Information 99
10.11.2 Amgen Introduction and Business Overview 99
10.11.3 Amgen Aflibercept Biosimilars Products Offered 100
10.12 Formycon 100
10.12.1 Formycon Company Information 100
10.12.2 Formycon Introduction and Business Overview 101
10.12.3 Formycon Aflibercept Biosimilars Products Offered 102
10.12.4 Formycon Recent Development 102
11 Opportunities, Challenges, Risks and Influences Factors Analysis 103
11.1 Aflibercept Biosimilars Industrial Chain Analysis 103
11.2 Aflibercept Biosimilars Market Dynamics 103
11.2.1 Aflibercept Biosimilars Industry Trends 103
11.2.2 Aflibercept Biosimilars Market Drivers 104
11.2.3 Aflibercept Biosimilars Market Challenges 105
11.2.4 Aflibercept Biosimilars Market Restraints 105
12 Marketing Strategy Analysis, Distributors 106
12.1 Sales Channel 106
12.2 Aflibercept Biosimilars Distributors 107
12.3 Aflibercept Biosimilars Downstream Customers 108
13 Research Findings and Conclusion 109
14 Appendix 110
14.1 Research Methodology 110
14.1.1 Methodology/Research Approach 110
14.1.2 Data Source 113
14.2 Author Details 116
14.3 Disclaimer 119

 

ページTOPに戻る


 

Summary

The global market for Aflibercept Biosimilars was estimated at US$ 9869.64 million in the year 2022, is projected to reach a revised size of US$ 10399.94 million by 2029, growing at a CAGR of 1.41 % during the forecast period 2023-2029.
North American market for Aflibercept Biosimilars was valued at $ 7639.71 million in 2022 and will reach $ 8459.36 million by 2029, at a CAGR of 1.74 % during the forecast period of 2023 through 2029.
Asia-Pacific market for Aflibercept Biosimilars was valued at $ 436.24million in 2022 and will reach $ 384.96 million by 2029, at a CAGR of -2.22% during the forecast period of 2023 through 2029.
Europe market for Aflibercept Biosimilars was valued at $ 1753.49 million in 2022 and will reach $ 1537.67 million by 2029, at a CAGR of 0.78% during the forecast period of 2023 through 2029.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Aflibercept Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Aflibercept Biosimilars.

The Aflibercept Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Aflibercept Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aflibercept Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

Market Segmentation
This report covers the Aflibercept Biosimilars segments by manufacturers, by Type, by Application, by region and country, and provides market size (value, volume and average price) and CAGR for the history and forecast period (2018-2022, 2023-2029), considering 2022 as the base year. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

By Company
Regeneron Pharmaceuticals
Bayer HealthCare
Kanghong Pharma
Biocon

Segment by Type
2mg
8mg

Segment by Application
Hospitals
Clinics
Others

By Region
North America
United States
Canada

Asia-Pacific
China
Japan
South Korea
India
Australia
Southeast Asia

Europe
Germany
France
U.K.
Italy
Russia

Latin America
Mexico
Brazil
Argentina
Colombia

Middle East & Africa
Turkey
Saudi Arabia
UAE

Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter Two: Detailed analysis of Aflibercept Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Aflibercept Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.



ページTOPに戻る


Table of Contents

1 Aflibercept Biosimilars Market Overview 1
1.1 Aflibercept Biosimilars Product Overview 1
1.2 Aflibercept Biosimilars Market by Type 3
1.2.1 2mg 3
1.2.2 8mg 4
1.3 Global Aflibercept Biosimilars Market Size by Type 6
1.3.1 Global Aflibercept Biosimilars Market Size Overview by Type (2018-2029) 7
1.3.2 Global Aflibercept Biosimilars Historic Market Size Review by Type (2018-2023) 8
1.3.3 Global Aflibercept Biosimilars Forecasted Market Size by Type (2024-2029) 10
1.4 Key Regions Market Size by Type 11
1.4.1 North America Aflibercept Biosimilars Sales Breakdown by Type (2018-2023) 11
1.4.2 Europe Aflibercept Biosimilars Sales Breakdown by Type (2018-2023) 13
1.4.3 Asia-Pacific Aflibercept Biosimilars Sales Breakdown by Type (2018-2023) 15
1.4.4 Latin America Aflibercept Biosimilars Sales Breakdown by Type (2018-2023) 17
1.4.5 Middle East and Africa Aflibercept Biosimilars Sales Breakdown by Type (2018-2023) 19
2 Aflibercept Biosimilars Market Competition by Company 22
2.1 Global Top Players by Aflibercept Biosimilars Sales (2018-2023) 22
2.2 Global Top Players by Aflibercept Biosimilars Revenue (2018-2023) 23
2.3 Global Top Players by Aflibercept Biosimilars Price (2018-2023) 24
2.4 Global Top Manufacturers Aflibercept Biosimilars Manufacturing Base Distribution, Sales Area, Product Type 25
2.5 Aflibercept Biosimilars Market Competitive Situation and Trends 25
2.5.1 Aflibercept Biosimilars Market Concentration Rate (2018-2023) 25
2.5.2 Global Largest Manufacturers by Aflibercept Biosimilars Sales and Revenue in 2022 26
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Aflibercept Biosimilars as of 2022) 27
2.7 Date of Key Manufacturers Enter into Aflibercept Biosimilars Market 28
2.8 Key Manufacturers Aflibercept Biosimilars Product Offered 28
2.9 Mergers & Acquisitions, Expansion 29
3 Aflibercept Biosimilars Status and Outlook by Region 32
3.1 Global Aflibercept Biosimilars Market Size and CAGR by Region: 2018 VS 2022 VS 2029 32
3.2 Global Aflibercept Biosimilars Historic Market Size by Region 32
3.2.1 Global Aflibercept Biosimilars Sales in Volume by Region (2018-2023) 32
3.2.2 Global Aflibercept Biosimilars Sales in Value by Region (2018-2023) 33
3.2.3 Global Aflibercept Biosimilars Sales (Volume & Value), Price and Gross Margin (2018-2023) 34
3.3 Global Aflibercept Biosimilars Forecasted Market Size by Region 34
3.3.1 Global Aflibercept Biosimilars Sales in Volume by Region (2024-2029) 34
3.3.2 Global Aflibercept Biosimilars Sales in Value by Region (2024-2029) 35
3.3.3 Global Aflibercept Biosimilars Sales (Volume & Value), Price and Gross Margin (2024-2029) 35
4 Aflibercept Biosimilars by Application 37
4.1 Aflibercept Biosimilars Market by Application 37
4.1.1 Hospitals 37
4.1.2 Clinics 38
4.1.3 Others 39
4.2 Global Aflibercept Biosimilars Market Size by Application 40
4.2.1 Global Aflibercept Biosimilars Market Size Overview by Application (2018-2029) 41
4.2.2 Global Aflibercept Biosimilars Historic Market Size Review by Application (2018-2023) 42
4.2.3 Global Aflibercept Biosimilars Forecasted Market Size by Application (2024-2029) 44
4.3 Key Regions Market Size by Application 46
4.3.1 North America Aflibercept Biosimilars Sales Breakdown by Application (2018-2023) 46
4.3.2 Europe Aflibercept Biosimilars Sales Breakdown by Application (2018-2023) 47
4.3.3 Asia-Pacific Aflibercept Biosimilars Sales Breakdown by Application (2018-2023) 49
4.3.4 Latin America Aflibercept Biosimilars Sales Breakdown by Application (2018-2023) 51
4.3.5 Middle East and Africa Aflibercept Biosimilars Sales Breakdown by Application (2018-2023) 53
5 North America Aflibercept Biosimilars by Country 56
5.1 North America Aflibercept Biosimilars Historic Market Size by Country 56
5.1.1 North America Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029 56
5.1.2 North America Aflibercept Biosimilars Sales in Volume by Country (2018-2023) 56
5.1.3 North America Aflibercept Biosimilars Sales in Value by Country (2018-2023) 57
5.2 North America Aflibercept Biosimilars Forecasted Market Size by Country 57
5.2.1 North America Aflibercept Biosimilars Sales in Volume by Country (2024-2029) 57
5.2.2 North America Aflibercept Biosimilars Sales in Value by Country (2024-2029) 58
6 Europe Aflibercept Biosimilars by Country 59
6.1 Europe Aflibercept Biosimilars Historic Market Size by Country 59
6.1.1 Europe Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029 59
6.1.2 Europe Aflibercept Biosimilars Sales in Volume by Country (2018-2023) 59
6.1.3 Europe Aflibercept Biosimilars Sales in Value by Country (2018-2023) 60
6.2 Europe Aflibercept Biosimilars Forecasted Market Size by Country 61
6.2.1 Europe Aflibercept Biosimilars Sales in Volume by Country (2024-2029) 61
6.2.2 Europe Aflibercept Biosimilars Sales in Value by Country (2024-2029) 62
7 Asia-Pacific Aflibercept Biosimilars by Region 63
7.1 Asia-Pacific Aflibercept Biosimilars Historic Market Size by Region 63
7.1.1 Asia-Pacific Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029 63
7.1.2 Asia-Pacific Aflibercept Biosimilars Sales in Volume by Region (2018-2023) 63
7.1.3 Asia-Pacific Aflibercept Biosimilars Sales in Value by Region (2018-2023) 64
7.2 Asia-Pacific Aflibercept Biosimilars Forecasted Market Size by Region 65
7.2.1 Asia-Pacific Aflibercept Biosimilars Sales in Volume by Region (2024-2029) 65
7.2.2 Asia-Pacific Aflibercept Biosimilars Sales in Value by Region (2024-2029) 66
8 Latin America Aflibercept Biosimilars by Country 67
8.1 Latin America Aflibercept Biosimilars Historic Market Size by Country 67
8.1.1 Latin America Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029 67
8.1.2 Latin America Aflibercept Biosimilars Sales in Volume by Country (2018-2023) 67
8.1.3 Latin America Aflibercept Biosimilars Sales in Value by Country (2018-2023) 68
8.2 Latin America Aflibercept Biosimilars Forecasted Market Size by Country 69
8.2.1 Latin America Aflibercept Biosimilars Sales in Volume by Country (2024-2029) 69
8.2.2 Latin America Aflibercept Biosimilars Sales in Value by Country (2024-2029) 69
9 Middle East and Africa Aflibercept Biosimilars by Country 71
9.1 Middle East and Africa Aflibercept Biosimilars Historic Market Size by Country 71
9.1.1 Middle East and Africa Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029 71
9.1.2 Middle East and Africa Aflibercept Biosimilars Sales in Volume by Country (2018-2023) 71
9.1.3 Middle East and Africa Aflibercept Biosimilars Sales in Value by Country (2018-2023) 72
9.2 Middle East and Africa Aflibercept Biosimilars Forecasted Market Size by Country 73
9.2.1 Middle East and Africa Aflibercept Biosimilars Sales in Volume by Country (2024-2029) 73
9.2.2 Middle East and Africa Aflibercept Biosimilars Sales in Value by Country (2024-2029) 73
10 Company Profiles 75
10.1 Regeneron Pharmaceuticals 75
10.1.1 Regeneron Pharmaceuticals Company Information 75
10.1.2 Regeneron Pharmaceuticals Introduction and Business Overview 76
10.1.3 Regeneron Pharmaceuticals Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023) 76
10.1.4 Regeneron Pharmaceuticals Aflibercept Biosimilars Products Offered 77
10.1.5 Regeneron Pharmaceuticals Recent Development 77
10.2 Bayer HealthCare 78
10.2.1 Bayer HealthCare Company Information 78
10.2.2 Bayer HealthCare Introduction and Business Overview 79
10.2.3 Bayer HealthCare Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023) 79
10.2.4 Bayer HealthCare Aflibercept Biosimilars Products Offered 79
10.2.5 Bayer HealthCare Recent Development 80
10.3 Kanghong Pharma 81
10.3.1 Kanghong Pharma Company Information 81
10.3.2 Kanghong Pharma Introduction and Business Overview 82
10.3.3 Kanghong Pharma Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023) 82
10.3.4 Kanghong Pharma Aflibercept Biosimilars Products Offered 83
10.3.5 Kanghong Pharma Recent Development 83
10.4 Biocon 84
10.4.1 Biocon Company Information 84
10.4.2 Biocon Introduction and Business Overview 85
10.4.3 Biocon Aflibercept Biosimilars Products Offered 86
10.4.4 Biocon Recent Development 86
10.5 AbbVie 86
10.5.1 AbbVie Company Information 87
10.5.2 AbbVie Introduction and Business Overview 87
10.5.3 AbbVie Aflibercept Biosimilars Products Offered 88
10.5.4 AbbVie Recent Development 88
10.6 Roche 88
10.6.1 Roche Company Information 89
10.6.2 Roche Introduction and Business Overview 89
10.6.3 Roche Aflibercept Biosimilars Products Offered 90
10.6.4 Roche Recent Development 90
10.7 Novartis 90
10.7.1 Novartis Company Information 91
10.7.2 Novartis Introduction and Business Overview 91
10.7.3 Novartis Aflibercept Biosimilars Products Offered 92
10.7.4 Novartis Recent Development 92
10.8 QILU Pharmaceutical 93
10.8.1 QILU Pharmaceutical Company Information 93
10.8.2 QILU Pharmaceutical Introduction and Business Overview 93
10.8.3 QILU Pharmaceutical Aflibercept Biosimilars Products Offered 94
10.8.4 QILU Pharmaceutical Recent Development 94
10.9 Regenxbio 95
10.9.1 Regenxbio Company Information 95
10.9.2 Regenxbio Introduction and Business Overview 96
10.9.3 Regenxbio Aflibercept Biosimilars Products Offered 96
10.9.4 Regenxbio Recent Development 96
10.10 Samsung Bioepis 97
10.10.1 Samsung Bioepis Company Information 97
10.10.2 Samsung Bioepis Introduction and Business Overview 97
10.10.3 Samsung Bioepis Aflibercept Biosimilars Products Offered 98
10.10.4 Samsung Bioepis Recent Development 98
10.11 Amgen 99
10.11.1 Amgen Company Information 99
10.11.2 Amgen Introduction and Business Overview 99
10.11.3 Amgen Aflibercept Biosimilars Products Offered 100
10.12 Formycon 100
10.12.1 Formycon Company Information 100
10.12.2 Formycon Introduction and Business Overview 101
10.12.3 Formycon Aflibercept Biosimilars Products Offered 102
10.12.4 Formycon Recent Development 102
11 Opportunities, Challenges, Risks and Influences Factors Analysis 103
11.1 Aflibercept Biosimilars Industrial Chain Analysis 103
11.2 Aflibercept Biosimilars Market Dynamics 103
11.2.1 Aflibercept Biosimilars Industry Trends 103
11.2.2 Aflibercept Biosimilars Market Drivers 104
11.2.3 Aflibercept Biosimilars Market Challenges 105
11.2.4 Aflibercept Biosimilars Market Restraints 105
12 Marketing Strategy Analysis, Distributors 106
12.1 Sales Channel 106
12.2 Aflibercept Biosimilars Distributors 107
12.3 Aflibercept Biosimilars Downstream Customers 108
13 Research Findings and Conclusion 109
14 Appendix 110
14.1 Research Methodology 110
14.1.1 Methodology/Research Approach 110
14.1.2 Data Source 113
14.2 Author Details 116
14.3 Disclaimer 119

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21 10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る